[The value of monitoring of qualitative content of onco-antigens in serum in diagnostics of malignant tumors].

The results of monitoring of qualitative content of 8 onco-antigens (CK, CA-242, CA-19-9, CA-125, REA, AFP, SCC, NSE) in serum of 414 patients are presented. The examination of 62 patients with tumors of different localization was carried our in dynamics before and after treatment. The monitoring of concentration of onco-antigens in serum permitted to apply early diagnostics of malignant process to 9 out of 28 patients with unclear clinical symptomatic. The technique informativeness is demonstrated in pre-clinical diagnostic and prognosis of course of oncological diseases. The possibility of transitory increase of concentration of certain onco-antigens under non-oncologic diseases returning to normal values after application of corresponding pharmaceutical treatment is revealed. The broader implementation of this technique into practice of public health is recommended.

[Effect of lysozyme on the growth of murine lymphoma and antineoplastic activity of cyclophosphamide]. / Vliianie lizotsima na rost myshinoi limfomy i protivoopukholevuiu aktivnost' tsiklofosfamida.

It was shown that hen egg-white lysozyme (LM) in the dose 100 mg/kg under the daily intragastral use slightly inhibited tumor grown or did not influence significantly upon it and did not change antitumor activity of cyclophosphamide. When used at mice C57Bl/6J with the transplanted ascitic or solid T-cell lymphoma EL4 (syngeneic system). On model of the same tumors in ascitic form at mice-hybrids (C57Bl/6J x DBA2)F1 (semisingeneic system) LM significantly potentiates antitumor activity of cyclophosphamide, though it had no effect on the rate of tumor growth. Potentiation of the effect of cyclophosphamide revealed itself in more slow development of ascite, increased mean life-span and the overall survival, appearance of completely cured animals. Our clinic-laboratory studies have revealed a sharp deficit of endogenic lysozyme in the blood serum of leukemic patients and extremely low lysozyme content in lavage liquid, from leukemic patients, with pneumonia. These data suggest that LM can be useful as a food additive in the complex treatment of oncological patients for enhancing antineoplastic chemotherapy efficacy.

[Certain biochemical features of leukocytes in blast crisis of chronic myelogenous leukemia]. / Nekotorye biokhimicheskie osobennosti leikotsitov pri blastnom krize khronicheskogo mieloleikoza.

The content of nuclear high mobility group (HMG) proteins, activities of ornithine decarboxylase (ODC), adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) and also glycosaminoglycan (GAG) content and composition were studied in leukocytes of patients with chronic myelogenous leukemia in the phase of blast crisis (BC CML). Myeloid and lymphoid cytochemical variants of BC CML differ by biochemical parameters. It is suggested, that the content of HMG-proteins, activities of ODC and PNP, and electrophoretic patterns of GAGs could be used in diagnostics of two main variants of BC CML.

[Effectiveness of various chemotherapy regimens for patients with chronic myeloid leukemia in blast crisis]. / Effektivnost' razlichnykh programm polikhimioterapii pri lechenii bol'nykh khronicheskim mieloleikozom v faze blastnogo kriza.

The evidence on the treatment of 146 cases of blastic (myeloid-101, lymphoblastic-45) crisis (BC) have been analyzed to evaluate the efficacy of different schemes of polychemotherapy (PCT) administered for blastic crisis myeloid leukemia (CML). The study of the 7 + 3, 7 + 3 + B. RP, VRP, RAP, VAP, CROMP. COP + Rub schemes as well as large doses of cytosar showed the 7 + 3 and RAP to be the most effective for myeloid BC and COP + Rub and VAP-for lymphoblastic one. Complete clinico-hematologic remission was 55 and 56%, respectively, in myeloid BC and 50 and 57%, respectively, in lymphoblastic BC. Relatively lower antitumor effect was recorded for the CROMP and RP in myeloid and the VRP in lymphoblastic crisis. Actuarial survival was assessed both for the entire CML group and each type of crisis and PCT scheme, and it was shown that more cases of lymphoblastic BC survived while fewer of them survive 3-5 years. However, 6-year survival rates were identical in both groups. Survival in the 7 + 3 group appeared to be higher than that in the VRP group suffering from lymphoblastic. BC. To summarize, the 7 + 3 and RAP schemes proved the most effective treatment for myeloid BC, while the COP + Rub and VAP for lymphoblastic BC.

[Is the cytogenetic verification of chronic myeloleukemia always obligatory?]. / Vsegda li obiazatel'na tsitogeneticheskaia verifikatsiia khronicheskogo mieloleikoza?

To elucidate feasibility of accurate diagnosis of chronic myeloid leukemia (CML) without cytogenetic and molecular-genetic investigations as well as to specify CML diagnostic criteria, clinicohematological parameters were compared in two groups of patients: with Ph'-chromosome and/or rearrangement of fragment bcr (group 1), with unknown karyotype in whom detection of bcr fragment rearrangement was not made. Clinicohematological parameters in both groups were close in absolute value and underwent parallel changes in the course of leukemia progression. In group 1, patients in progressive and blastic phase compared to patients in chronic phase had a 14-fold increase in the number of additional cytogenetic anomalies. In patients with tumor transformation fragment bcr underwent rearrangement according to type B2A2. Thus, the diagnosis of typical CML variants is feasible without detection of Ph'-chromosome and/or rearrangement of bcr fragment. It is especially true and essential for patients in the chronic phase. The data obtained provide more accurate diagnostic criteria of CML.

[Experience with the use of reaferon (alfa 2-interferon) for treating patients with chronic myeloleukemia]. / Opyt primeneniia reaferona (al'fa 2-interferona) dlia lecheniia bol'nykh khronicheskim mieloleikozom.

The effectiveness of domestic alpha 2-interferon preparation reaferon was studied in vivo and in vitro for eradication of pathological hemopoietic clone in chronic myeloid leukemia. Reaferon administration for 1-30 months produced cytogenetic remission in 7%, hematological remission in 21%, partial hematological remission in 36% of the patients. Reaferon is indicated in chronic myeloid leukemia without splenomegaly. In the disease progression reaferon is uneffective. Mechanism of reaferon therapeutic action comprises three components: a direct antiproliferative effect on hemopoietic precursor cells, activation of cellular immunity, an effect on stem cell microenvironment.

[Thymidine kinase activity in leukocytes from patients with chronic myeloid leukemia at various periods in the disease]. / Aktivnost' timidinkinazy v leikotsitakh bol'nykh khronicheskim mieloleikozom v razlichnye periody zabolevaniia.

The level of thymidine kinase activity in the premature leukocytes of patients with chronic myeloleukemia during the stable phase was shown to serve as a measure of the disease development. Considerable variations in thymidine kinase activity in blast cells in myeloid and lymphoid blast crises demonstrated that analysis of the enzyme activity might be used in the biochemical diagnosis of blast crisis in chronic myeloleukemia simultaneously with the enzymes of purine metabolism--ADA and PNP. During cell differentiation, the activity of thymidine kinase was decreased and in the myeloid cells the enzymatic activity was much higher of that in lymphoid cells as shown by investigations using blast cells of patients with blast crisis in chronic myeloleukemia, cells K-562, thymocytes, spleen and peripheric blood lymphocytes. Isozyme thymidine kinase I was mainly responsible for the rate of enzymatic activity in premature leukocytes of patients with chronic myeloleukemia regardless of the disease stage.

[The prognostic role of determining spontaneous leukocyte DNA damage and that occurring during chemotherapy in leukemia patients]. / Prognosticheskaia rol' opredeleniia spontannykh i voznikaiushchikh v protsesse khimioterapii povrezhdenii DNK leikotsitov bol'nykh leikozami.

The authors studied spontaneous DNA damages and the extra plan synthesis of DNA in various leukemias (chronic lympholeukemia, chronic myeloleukemia, acute leukemia) to predict the natural course of leukemias and the efficiency of chemotherapy. The level of genuine DNA breaks, which had been determined by the nic-translation test, was lower in peripheral blood cell DNA in all leukemias than that in the lymphocytes and granulocytes from donors. On the contrary, the levels of alkaline-labile DNA sites and nuclear matrix protein-bound DNA in the mature and maturing leukemia cells are high and decrease with progression of chronic lympholeukemia and chronic myeloleukemia. The extra plan DNA synthesis largely reflects the cellular levels of genuine DNA breaks, and the ultraviolet-induced DNA repair capacity is the highest in the lymphocytes in chronic lympholeukemia and particularly in the blasts in acute leukemia. The efficiency of chemotherapy was predicted during chemotherapy from the intensity of formation of genuine blast cell DNA breaks.

[Enzymatic markers in chronic myeloleukemia and their importance for identifying a blast crisis]. / Enzimaticheskie markery pri khronicheskom mieloleikoze i ikh znachenie dlia identifikatsii blastnogo kriza.

The paper summarizes data on the activity of adenosine deaminase and purine nucleoside phosphorylase which contribute to purine nucleotide degradation. The enzyme activity was studied in leukocytes of varying degree of differentiation obtained from 29 cases with chronic phase of chronic myeloid leukemia (CML), 19 patients with acute phase of the disease and from blasts of 32 cases with CML-associated blast crisis. In CML patients, lymphocytes of leukemic clones showed various levels of activity of the enzymes. Myeloid and lymphoid blast crises proved biochemically heterogeneous. The possibility to establish the nature of blast crisis in CML on the basis of profile of adenosine deaminase and purine nucleoside phosphorylase in blasts is discussed.

[Morphocytochemical reaction of the lymph nodes in dogs to the administration of lysozyme]. / Morfotsitokhimicheskaia reaktsiia limfaticheskikh uzlov sobak na vvedenie lizotsima.

By means of morphological, morphometrical and histochemical methods pelvic and tracheobronchial lymph nodes have been studied in dogs and concentration of lysozyme has been estimated in blood serum, in lymph and the lymph nodes after a single intramuscular injection of lysozyme (2 mg/kg of body mass). In the material investigated total concentration of lysozyme reaches its maximal values in 6 h after injection, then it gradually decreases and in 48 h reaches its control level. Morphometrically changes in cell composition are revealed predominantly of immune-competent cells in T- and B-dependent zones of the lymph nodes. Thus, the volumetric part of lymphoblasts in the germinative centers of the lymphoid nodules reaches its maximal indices by 48 h after lysozyme injection, while plasmatization of the paracortical zone and of medullary cords increases up to the 7th day. By the 14th day the volumetric part of lymphoblasts, immunoblasts and plasmocytes decreases gradually, and in 21 days after injection of the drug contents of the blast forms of the cells in the structural-functional zones of the lymph nodes does not differ from that in the control. The data obtained demonstrate the immunomorphological rearrangement of the lymph nodes in response to the exogenic lysozyme administration.

[Characteristics of the recovery of the erythron after blood loss in prodigiozan-stimulated mice]. / Osobennosti vosstanovleniia éritroidnogo rostka posle krovopoteri u myshei, stimulirovannykh profigiozanom.

The effect of bacterial polysaccharide prodigiozan on recovery after single acute blood loss (2.5 per cent of the body weight) was studied on female mice CBA x C57Bl (F1). When administered intravenously in a dose of 0.5 mg/kg to healthy animals without blood loss prodigiozan had no significant effect on erythropoiesis. Prophylactic administration of the drug 24 hours before blood loss promoted more rapid and intensive mobilization of erythropoiesis: increasing of the levels of 59Fe incorporation into the bone marrow erythroid cells and the number of erythroid cells in the spleen as compared to those in nonstimulated animals. This is probably connected with prodigiozan-mediated stimulation of stem hemopoietic cell proliferation.

[Leukocyte glycosaminoglycans in various forms of myelo- and lymphoproliferative blood diseases]. / Glikozaminoglikany leikotsitov pri raznykh formakh mielo- i limfoproliferativnykh zabolevanii sistemy krovi.

The level and composition of glycosaminoglycans (GAG) were studied in leukocytes of healthy donors and patients with different forms of leukemia. GAG level was found to increase in chronic myeloproliferative disorders. This parameter was far below the norm in most cases of acute leukemia. An evaluation of GAG profile established a relationship between cell GAG level variation, the type of proliferating cells and leukemic transformation. Peculiarities of GAG profile in myeloid and lymphoid cells were identified. It was shown that a study of GAG in leukocytes of leukemic patients may contribute to identification of blast elements and differential diagnosis between leukemia types.

[Metabolism and function of phagocytes after combined administration of immunosuppressants and biologically active substances]. / Metabolizm i funktsii fagotsitov pri sochetannom primenenii immunodepressorov i biologicheski aktivnykh veshchestv.

Metabolism and function of mouse phagocytes were studied experimentally under conditions of immunosuppression with biologically active substances. It was shown by the cytochemical methods with the use of cytophotometry that strong immunosuppression with azathioprin, prednisolone, especially with their combination induced inhibition of the enzymatic systems responsible for synthetic and energy processes in macrophages. Prodigiosan, a bacterial lipopolysaccharide, and lysozyme promoted elimination of the unfavourable effect of the immunosuppressors on macrophage metabolism, normalizing the decreased activity of certain enzymes and markedly activating the enzymes involved in detoxification and phagocytosis. The lysozyme effect did not depend on the type of drug immunosuppression. The efficiency of prodigiosan was the highest after administration of prednisolone or its combination with azathioprin. Its effect was lower after immunosuppression with azathioprin alone. During allotransplantation, prodigiosan also promoted the recovery of the leukocyte adsorption and digestive capacity impaired by prednisolone and tis combination with azathioprin. The differential use of the biologically active substances is a promising trend in control of complications due to immunosuppression therapy.

[Effect of prodigiozan and lysozyme on the surface structures of macrophages after immunosuppression]. / Vliianie prodigiozana i lizotsima na poverkhnostnye struktury makrofagov v usloviiakh immunodepressii.

The state of macrophage surface structures is closely connected with the function 1 capacity of these cells. Peritoneal macrophages from mice subjected to strong 10-day immunosuppression with azathioprine (60 mg/kg), prednisolone (50 mg/kg) or their combination (25 and 30 mg/kg, respectively) were investigated with scanning electron microscopy. Azathioprine and especially its combination with prednisolone induced pronounced degenerative affections in the macrophages and lymphocytes, smoothing of their surfaces, predominance of large spread macrophages, and impairment of the intracellular cooperation. The macrophage alteration under the action of prednisolone was less pronounced. Prodigiozan, a bacterial polysaccharide (0.5 mg/kg) administered on the 4th and 9th days of the immunosuppression increased the macrophage resistance mainly to the damaging effect of prednisolone and was low effective after administration of azathioprine. The effect of lysozyme injected intramuscularly in a dose of 0.5 mg/kg daily within a period of the 3rd to the 10th days of the use of the immunosuppressants was evident from activation of the surface structures of the small macrophages and lymphocytes and reduction of cell alterations independent of the type of the immunosuppressants used. This indicates the necessity of a differential approach to the use of the macrophage activators for correcting the decreased infection resistance after medicamentous immunosuppression.